Huprines for Alzheimer's disease drug development

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Drug Discovery

• Publication date

  2008-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1517/17460441.3.1.65PMID 23480140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease

  2013cited by this paper
• Therapeutic perspectives in Alzheimer's disease.

  2012cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.

  2007cited by this paper
• Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.

  2007cited by this paper
• Extensive SAR and computational studies of 3-{4-[(benzylmethylamino)methyl]phenyl}-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives.

  2007cited by this paper
• Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?

  2007cited by this paper
• A small molecule targeting the multifactorial nature of Alzheimer's disease.

  2007cited by this paper
• Therapies for Alzheimer's disease

  2007cited by this paper
• Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

  2006cited by this paper
• Therapeutic Perspectives in Alzheimers Disease

  2006cited by this paper
• Binding of 13-amidohuprines to acetylcholinesterase: exploring the ligand-induced conformational change of the gly117-gly118 peptide bond in the oxyanion hole.

  2006cited by this paper
• Do cholinergic therapies have disease‐modifying effects in Alzheimer's disease?

  2006cited by this paper
• Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy.

  2006cited by this paper
• Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.

  2006cited by this paper
• Therapeutic approaches to Alzheimer's disease.

  2006cited by this paper
• Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease

  2006influential reference
• A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis.

  2006cited by this paper
• Dimeric and hybrid anti-Alzheimer drug candidates.

  2006cited by this paper
• Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor

  2006cited by this paper
• Current Pharmacotherapy for Alzheimer ’ s Disease

  2006cited by this paper
• Preclinical Evidence of Neuroprotection by Cholinesterase Inhibitors

  2006cited by this paper
• Current pharmacotherapy for Alzheimer's disease.

  2006cited by this paper
• Amyloid beta: the alternate hypothesis.

  2006cited by this paper
• Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

  2006cited by this paper
• Alzheimer disease: progress or profit?

  2006cited by this paper
• Acetylcholinesterase triggers the aggregation of PrP 106-126.

  2006cited by this paper
• What Constitutes Clinical Evidence for Neuroprotection in Alzheimer Disease: Support for the Cholinesterase Inhibitors?

  2006cited by this paper
• Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

  2005cited by this paper
• Conversion of a-helices into ,f-sheets features in the formation of the scrapie prion proteins

  2005cited by this paper
• (±)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration

  2005cited by this paper
• Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation.

  2005cited by this paper
• Effects of (±)-huprine Y and (±)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors

  2005cited by this paper
• Targeting acetylcholinesterase and butyrylcholinesterase in dementia.

  2005cited by this paper
• Rational approach to discover multipotent anti-Alzheimer drugs.

  2005cited by this paper
• Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

  2005cited by this paper
• Prion protein (PrPc) promotes beta-amyloid plaque formation.

  2005cited by this paper
• Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.

  2005cited by this paper
• Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer’s disease

  2005cited by this paper
• Prion protein (PrP c ) promotes -amyloid plaque formation

  2005cited by this paper
• Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.

  2005cited by this paper
• An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds.

  2004cited by this paper
• The Practice of Medicinal Chemistry

  2004cited by this paper
• Cholinesterase inhibitors: new roles and therapeutic alternatives.

  2004cited by this paper
• Acetylcholinesterase-Aβ Complexes Are More Toxic than Aβ Fibrils in Rat Hippocampus : Effect on Rat β-Amyloid Aggregation, Laminin Expression, Reactive Astrocytosis, and Neuronal Cell Loss

  2004cited by this paper
• Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss.

  2004cited by this paper
• Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis

  2004cited by this paper
• Improving the decision-making process in structural modification of drug candidates: reducing toxicity.

  2004cited by this paper
• Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells.

  2004cited by this paper
• Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.

  2004influential reference
• Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids.

  2003cited by this paper
• Acute effects of huperzine A and tacrine on rat liver.

  2003cited by this paper
• Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease.

  2003cited by this paper
• beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies.

  2003cited by this paper
• Synthesis of diastereomeric 13-amido-substituted huprines as potential high affinity acetylcholinesterase inhibitors

  2003cited by this paper
• Neuroprotective effects of (+/-)-huprine Y on in vitro and in vivo models of excitoxicity damage.

  2003cited by this paper
• The Magnitude of Dementia Occurrence in the World

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement.

  2002cited by this paper
• 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.

  2002cited by this paper
• Homodimeric tacrine congeners as acetylcholinesterase inhibitors.

  2002cited by this paper
• Interaction of a new potent anticholinesterasic compound (+/-)huprine X with muscarinic receptors in rat brain.

  2002cited by this paper
• Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.

  2001cited by this paper
• Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.

  2001cited by this paper
• Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt–Jakob disease

  2001cited by this paper
• A structure-based design approach to the development of novel, reversible AChE inhibitors.

  2001cited by this paper
• Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase.

  2001cited by this paper
• A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation.

  2001cited by this paper
• Synthesis of tacrine analogues and their structure-activity relationships.

  2000influential reference
• New Syntheses of rac-Huperzine A and its rac-7-Ethyl-Derivative. Evaluation of Several Huperzine A Analogues as Acetylcholinesterase Inhibitors

  2000cited by this paper
• New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.

  2000cited by this paper
• Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.

  2000cited by this paper
• Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex.

  1999cited by this paper
• Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A

  1999influential reference
• Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.

  1999cited by this paper
• SYNTHESIS OF AN 11-UNSUBSTITUTED ANALOGUE OF ()-HUPERZINE A

  1999cited by this paper
• HUPERZINE A : A NOVEL ACETYLCHOLINESTERASE INHIBITOR

  1999cited by this paper
• Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis.

  1999cited by this paper
• The secretion of amyloid β-peptides is inhibited in the tacrine-treated human neuroblastoma cells

  1998cited by this paper
• Stable Complexes Involving Acetylcholinesterase and Amyloid-β Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer’s Fibrils

  1998cited by this paper
• The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells.

  1998cited by this paper
• Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.

  1998cited by this paper
• Enantioselective synthesis of tacrine–huperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assignments by X-ray diffraction analysis

  1998cited by this paper
• Origin of the catalytic power of acetylcholinesterase: Computer simulation studies

  1998cited by this paper
• Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase

  1997cited by this paper
• Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate

  1997cited by this paper
• Structure of acetylcholinesterase complexed with the nootropic alkaloid, (–)-huperzine A

  1997cited by this paper
• Easy synthesis of 7-alkylbicyclo[3.3.1]non-6-en-3-ones by silica gel-promoted fragmentation of 3-alkyl-2-oxaadamant-1-yl mesylates

  1996cited by this paper
• Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase

  1996cited by this paper
• Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

  1996cited by this paper
• The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase.

  1996cited by this paper
• Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides

  1995cited by this paper
• Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides.

  1995cited by this paper
• Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.

  1994influential reference
• An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes.

  1993cited by this paper
• Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins.

  1993cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties

  1992cited by this paper
• Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein

  1991cited by this paper
• Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat

  1989cited by this paper

• Advances in the structural modification of Alzheimer's disease drug - Huperzine A.

  2024cites this paper
• Tacrine-Based Hybrids: Past, Present, and Future

  2023cites this paper
• Strychnos alkaloids: total synthesis, characterization, DFT investigations, and molecular docking with AChE, BuChE, and HSA

  2022cites this paper
• Huprine Y - tryptophan heterodimers with potential implication to Alzheimer's disease treatment.

  2021cites this paper
• Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015–Present: Synthesis and Biological Activity

  2020cites this paper
• In vitro biolayer interferometry analysis of acetylcholinesterase as a potential target of aryl-organophosphorus flame-retardants.

  2020cites this paper
• Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice.

  2020cites this paper
• Donepezil Derivatives Targeting Amyloid-β cascade in Alzheimer's Disease.

  2019cites this paper
• The Structural Hybrids of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease: A Review

  2019cites this paper
• Binding free energy calculations to rationalize the interactions of huprines with acetylcholinesterase

  2018cites this paper
• Synthesis of Novel Agents for the treatment of Infectious and Neurodegenerative diseases

  2018cites this paper
• Multitarget Anti-Alzheimer Hybrid Compounds: Do They Work In Vivo?

  2017cites this paper
• Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy

  2017cites this paper
• Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids.

  2017cites this paper
• Design and prediction of new acetylcholinesterase inhibitor via quantitative structure activity relationship of huprines derivatives

  2016cites this paper
• AVCRI104P3, a novel multitarget compound with cognition-enhancing and anxiolytic activities: studies in cognitively poor middle-aged mice.

  2015cites this paper
• Rapid identification of anti-inflammatory compounds from Tongmai Yangxin Pills by liquid chromatography with high-resolution mass spectrometry and chemometric analysis.

  2015cites this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cites this paper
• Expanding the Multipotent Profile of Huprine-Tacrine Heterodimers as Disease-Modifying Anti-Alzheimer Agents

  2012cites this paper
• Huprines as a new family of dual acting trypanocidal–antiplasmodial agents

  2011cites this paper
• Novel Huprine Derivatives with Inhibitory Activity toward β‐Amyloid Aggregation and Formation as Disease‐Modifying Anti‐Alzheimer Drug Candidates

  2010cites this paper
• Improved synthetic pathway for the derivatization of huprine scaffold

  2010cites this paper